These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37905353)

  • 1. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
    Henry Z; Villar Fimbel S; Bendelac N; Perge K; Thivolet C
    Diabetes Obes Metab; 2024 Feb; 26(2):557-566. PubMed ID: 37905353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
    Rizzi A; Tartaglione L; Lucaccini Paoli L; Leo ML; Popolla V; Viti L; Barberio A; Di Leo M; Pontecorvi A; Pitocco D
    Diabetes Obes Metab; 2024 Sep; 26(9):4078-4086. PubMed ID: 39010292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
    Grassi B; Gómez AM; Calliari LE; Franco D; Raggio M; Riera F; Castro M; McVean J; van den Heuvel T; Arrieta A; Castañeda J; Cohen O
    Diabetes Obes Metab; 2023 Jun; 25(6):1688-1697. PubMed ID: 36789699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
    Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    BMC Med; 2024 Apr; 22(1):175. PubMed ID: 38659016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the usage of an open-source automated insulin delivery system and the MiniMed™ 780 G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group.
    Landau Z; Lebenthal Y; Mazor-Aronovitch K; Brener A; Levek N; Jacobi-Polishook T; Ben Ari T; Abiri S; Haim A; Nir J; Rachmiel M; Pinhas-Hamiel O
    Endocrine; 2024 Jun; 84(3):943-950. PubMed ID: 38225516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control.
    Lombardo F; Passanisi S; Alibrandi A; Bombaci B; Bonfanti R; Delvecchio M; Di Candia F; Mozzillo E; Piccinno E; Piona CA; Rigamonti A; Scialabba F; Maffeis C; Salzano G
    Diabetes Technol Ther; 2023 Jun; 25(6):404-413. PubMed ID: 36763343
    [No Abstract]   [Full Text] [Related]  

  • 9. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
    Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
    [No Abstract]   [Full Text] [Related]  

  • 10. Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial - study protocol.
    Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C; Benhalima K
    BMC Pregnancy Childbirth; 2023 Mar; 23(1):180. PubMed ID: 36927458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world performance of the MiniMed™ 670G system in Europe.
    Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data on the Minimed 780G advanced hybrid closed-loop system use during type 1 diabetes pregnancy: One centre observational study.
    Munda A; Kovacic C; Pongrac Barlovic D
    J Diabetes Complications; 2024 Aug; 38(8):108795. PubMed ID: 38878423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
    Benhamou PY; Adenis A; Lebbad H; Tourki Y; Heredia MB; Gehr B; Franc S; Charpentier G
    Diabetes Obes Metab; 2023 Jun; 25(6):1607-1613. PubMed ID: 36751978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
    Arunachalum S; Velado K; Vigersky RA; Cordero TL
    J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy.
    Davis GM; Peters AL; Bode BW; Carlson AL; Dumais B; Vienneau TE; Huyett LM; Ly TT
    Diabetes Care; 2023 Apr; 46(4):742-750. PubMed ID: 36787903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes.
    Lynch J; Kanapka LG; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Calhoun P; Beck RW
    Diabetes Technol Ther; 2022 Oct; 24(10):726-736. PubMed ID: 36173238
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated insulin delivery among adults with type 1 diabetes for up to 2 years: a real-world, multicentre study.
    Donaldson LE; Fourlanos S; Vogrin S; MacIsaac RJ; Colman PG; McAuley SA
    Intern Med J; 2024 Jan; 54(1):121-128. PubMed ID: 37255209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis.
    Yang Q; Zeng B; Hao J; Yang Q; Sun F
    Diabetes Obes Metab; 2024 Sep; 26(9):3753-3763. PubMed ID: 38888056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.